A world-class specialty pharmaceutical company

Our ambition is to become a leading specialty pharmaceutical company meeting the needs of patients around the world. With our broad portfolio of marketed and development-stage respiratory products we’re making good progress towards achieving our goal.

Our technologies

We’re using our proprietary technologies to develop a range of therapies for asthma and chronic obstructive pulmonary disease (COPD).

Our products

Our novel NIOX® products are used to help improve asthma management around the world, and we market the COPD therapy Tudorza® in the United States.

Our pipeline

We have a broad range of respiratory medicines in development, and our lead asthma treatment was approved in the UK.

About us

We’re a world-class specialty pharmaceutical company focused on asthma and COPD.

Careers

We’re a rapidly growing company with a range of exciting career opportunities.

Investors

Circassia is listed on the London Stock Exchange under the ticker CIR.

Press Releases

More press releases

Share Price

Full share price chart

Annual Report

Read the Annual Report (PDF)